Article Text
Therapeutics
Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications
Statistics from Altmetric.com
D P Tashkin
Dr D P Tashkin, University of California, Los Angeles, Los Angeles, CA, USA; dtashkin@mednet.ucla.edu
STUDY DESIGN
Design:
randomised placebo-controlled trial (Understanding Potential Long-Term Impacts on Function with Tiotropium [UPLIFT]). ClinicalTrials.gov NCT00144339.
Allocation concealment:
concealed.*
Blinding:
blinded (clinicians, patients, data collectors, and outcome adjudication committee).*
STUDY QUESTION
Setting:
490 centres in 37 countries worldwide.
Patients:
5993 patients ⩾40 years of age (mean age 65 y, 75% men) who had COPD, a history of ⩾10 pack-years of smoking, and postbronchodilation FEV1 ⩽70% of predicted and ⩽70% of FVC. Exclusion criteria included a history of asthma …
Footnotes
Source of funding: Boehringer Ingelheim and Pfizer.